Capricor Therapeutics (CAPR) Other Operating Expenses (2019 - 2026)
Capricor Therapeutics' (CAPR) quarterly Other Operating Expenses came in at -$81143.0 in Q1 2026, up 46.15% year-on-year from -$55521.8 in Q1 2025, and down 1085.26% quarter-over-quarter from -$6846.0 in Q3 2025.
Capricor Therapeutics (CAPR) Other Operating Expenses (2019 - 2026) Analysis & Trends
Capricor Therapeutics' Other Operating Expenses history runs 8 years deep, the most recent figure standing at -$81143.0 for Q1 2026.
- On a quarterly basis, Other Operating Expenses rose 46.15% year-over-year to -$81143.0 in Q1 2026; TTM through Mar 2026 was -$87989.0, a 93.26% increase from a year earlier, with the FY2025 full-year figure at -$157519.0, down 39.64% from the prior year.
- Other Operating Expenses retreated to -$81143.0 in Q1 2026 per CAPR's latest filing, from -$6846.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $17389.0 in Q2 2023 and bottomed at -$1.1 million in Q3 2024.
- The 5-year median for Other Operating Expenses is -$13649.0 (2024), against an average of -$113244.7.
- Across the five-year window, Other Operating Expenses surged 149.81% in 2023 and plunged 21063.16% in 2024, its largest moves.
- Year by year, Other Operating Expenses stood at -$34266.0 in 2022, then surged by 98.09% to -$653.0 in 2023, then plunged by 1990.2% to -$13649.0 in 2024, then jumped by 49.84% to -$6846.0 in 2025, then slumped by 1085.26% to -$81143.0 in 2026.
- Per Business Quant, the three latest CAPR Other Operating Expenses figures stand at -$81143.0 (Q1 2026), -$6846.0 (Q3 2025), and -$150673.0 (Q1 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Capricor Therapeutics | 1.12 Bn | 1.12 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -81,143.00 |
| Sep 30, 2025 | -6,846.00 |
| Mar 31, 2025 | -150,673.00 |
| Dec 31, 2024 | -13,649.00 |
| Sep 30, 2024 | -1.14 Mn |
| Mar 31, 2024 | 1,013.00 |
| Dec 31, 2023 | -653.00 |
| Sep 30, 2023 | -5,388.00 |
| Jun 30, 2023 | 17,389.00 |
| Mar 31, 2023 | -38,481.00 |
| Dec 31, 2022 | -34,266.00 |
| Jun 30, 2022 | -34,912.00 |
| Mar 31, 2022 | 15,699.00 |
| Dec 31, 2021 | -28,955.00 |
| Sep 30, 2021 | 13,915.00 |
| Jun 30, 2021 | -2,725.00 |
| Mar 31, 2020 | -44,844.00 |
| Jun 30, 2019 | -2,720.00 |